Innovent Biologics, Inc. (INNOVENT) cash flow statement
HKSE · Healthcare · Biotechnology · 8,754 employees · CEO De-Chao Yu
- Price
- HK$80.65 +1.13%
- Market cap
- HK$141B
- Enterprise value
- CN¥104B
- Last report
- Q2 '26 filed 2026-06-30
- Next report
- 2027-03-31
In Q2 '26 Innovent Biologics, Inc. (INNOVENT) generated CN¥3.74B of operating cash flow, invested CN¥182M in capital expenditure and kept CN¥3.57B of free cash flow. Over the last two half-years free cash flow was CN¥13B.
Cash flow
| Cash flow | Trend | Q4 '20 | Q2 '21 | Q4 '21 | Q2 '22 | Q4 '22 | Q2 '23 | Q4 '23 | Q2 '24 | Q4 '24 | Q2 '25 | Q4 '25 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||||||
| Net income | -CN¥390M | -CN¥1B | -CN¥1.73B | -CN¥950M | -CN¥1.23B | -CN¥139M | -CN¥889M | -CN¥393M | CN¥298M | CN¥834M | -CN¥20.4M | CN¥1.25B | |
| Depreciation & amortization | CN¥29.3M | CN¥90.6M | CN¥116M | CN¥122M | CN¥199M | CN¥186M | CN¥198M | CN¥199M | CN¥217M | CN¥268M | CN¥336M | CN¥332M | |
| Stock-based compensation | CN¥248M | CN¥239M | CN¥263M | CN¥261M | CN¥208M | CN¥227M | CN¥347M | CN¥298M | CN¥259M | CN¥342M | CN¥0 | CN¥385M | |
| Deferred income tax | CN¥59.9M | CN¥822M | CN¥0 | CN¥101M | -CN¥858M | CN¥96.9M | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | |
| Change in working capital | CN¥51.2M | -CN¥828M | CN¥557M | -CN¥273M | CN¥248M | -CN¥333M | CN¥828M | -CN¥119M | CN¥569M | -CN¥1.17B | CN¥8.86B | CN¥1.88B | |
| Other non-cash items | CN¥438M | -CN¥336M | -CN¥219M | -CN¥67.6M | CN¥321M | -CN¥660M | CN¥286M | -CN¥200M | CN¥160M | CN¥154M | CN¥487M | -CN¥109M | |
| Operating cash flow | CN¥436M | -CN¥1.02B | -CN¥1.01B | -CN¥807M | -CN¥1.11B | -CN¥623M | CN¥771M | -CN¥216M | CN¥1.5B | CN¥434M | CN¥9.66B | CN¥3.74B | |
| Investing | |||||||||||||
| Capital expenditure | -CN¥455M | -CN¥348M | -CN¥717M | -CN¥429M | -CN¥468M | -CN¥598M | -CN¥521M | -CN¥700M | -CN¥1.02B | -CN¥253M | -CN¥445M | -CN¥182M | |
| Purchases of investments | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | -CN¥16.8B | -CN¥17.2B | |
| Sales / maturities of investments | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥9.97B | CN¥8.38B | |
| Other investing | -CN¥3.78B | CN¥131M | -CN¥1.76B | CN¥808M | -CN¥1.35B | CN¥1.32B | -CN¥1.2B | CN¥146M | -CN¥612M | -CN¥1 | CN¥145M | CN¥0 | |
| Investing cash flow | -CN¥4.24B | -CN¥217M | -CN¥2.48B | CN¥379M | -CN¥1.81B | CN¥725M | -CN¥1.72B | -CN¥554M | -CN¥612M | CN¥419M | -CN¥7.17B | -CN¥8.96B | |
| Financing | |||||||||||||
| Net debt issued / repaid | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | -CN¥330M | CN¥0 | CN¥0 | -CN¥573M | -CN¥488M | |
| Other financing (incl. tax on vested shares) | CN¥2.73B | CN¥4.5B | CN¥500M | CN¥224M | CN¥2.67B | CN¥245M | CN¥2.34B | CN¥69.3M | -CN¥346M | CN¥163M | -CN¥5.13M | CN¥18.8M | |
| Financing cash flow | CN¥2.73B | CN¥4.5B | CN¥500M | CN¥224M | CN¥2.67B | CN¥245M | CN¥2.34B | -CN¥261M | -CN¥346M | CN¥766M | CN¥4.05B | -CN¥453M | |
| Summary | |||||||||||||
| FX effect on cash | -CN¥618M | -CN¥82.7M | -CN¥114M | CN¥196M | -CN¥77.5M | -CN¥30.7M | CN¥23.9M | -CN¥1.6M | CN¥14.3M | CN¥6.27B | -CN¥5.55B | CN¥13.2B | |
| Net change in cash | -CN¥846M | CN¥1.01B | -CN¥1.55B | -CN¥3.68M | -CN¥168M | CN¥158M | CN¥707M | -CN¥516M | -CN¥1.71B | CN¥7.89B | CN¥993M | CN¥7.49B | |
| Free cash flow (OCF - capex) | -CN¥19M | -CN¥1.36B | -CN¥1.73B | -CN¥1.24B | -CN¥1.58B | -CN¥1.22B | CN¥249M | -CN¥915M | CN¥1.24B | CN¥392M | CN¥9.43B | CN¥3.57B | |
| Cash flow | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||||
| Net income | -CN¥544M | -CN¥716M | -CN¥5.87B | -CN¥1.72B | -CN¥859M | -CN¥2.73B | -CN¥2.17B | -CN¥1.14B | -CN¥78.6M | CN¥839M | |
| Depreciation & amortization | CN¥54.6M | CN¥61.1M | CN¥64.1M | CN¥86.4M | CN¥85.6M | CN¥205M | CN¥319M | CN¥385M | CN¥420M | CN¥601M | |
| Stock-based compensation | CN¥8.5M | CN¥29.3M | CN¥53.4M | CN¥153M | CN¥403M | CN¥502M | CN¥469M | CN¥574M | CN¥557M | CN¥663M | |
| Deferred income tax | -CN¥41.3M | -CN¥8.93M | -CN¥42.7M | -CN¥14.5M | CN¥402M | CN¥50.4M | CN¥0 | CN¥0 | CN¥0 | CN¥0 | |
| Change in working capital | -CN¥11.9M | CN¥43.2M | CN¥421M | -CN¥141M | -CN¥334M | -CN¥90.3M | CN¥310M | CN¥403M | CN¥404M | CN¥7.94B | |
| Other non-cash items | CN¥172M | CN¥99.2M | CN¥4.36B | -CN¥28.2M | -CN¥5.34M | CN¥37.5M | -CN¥847M | -CN¥70.5M | -CN¥14.4M | -CN¥46.5M | |
| Operating cash flow | -CN¥363M | -CN¥492M | -CN¥1.02B | -CN¥1.66B | -CN¥308M | -CN¥2.02B | -CN¥1.92B | CN¥148M | CN¥1.29B | CN¥10B | |
| Investing | |||||||||||
| Capital expenditure | -CN¥58.4M | -CN¥91M | -CN¥313M | -CN¥366M | -CN¥772M | -CN¥1.85B | -CN¥1.38B | -CN¥1.12B | -CN¥1.03B | -CN¥270M | |
| Acquisitions | CN¥4.22M | CN¥4.76M | CN¥179M | CN¥70.5M | CN¥88.7M | -CN¥630M | CN¥0 | CN¥0 | -CN¥900M | CN¥0 | |
| Purchases of investments | -CN¥817M | -CN¥1.12B | -CN¥786M | -CN¥4.85B | -CN¥11.6B | -CN¥10.3B | -CN¥10.3B | -CN¥9.41B | -CN¥10.5B | -CN¥21.1B | |
| Sales / maturities of investments | CN¥295M | CN¥851M | CN¥1.93B | CN¥2.58B | CN¥7.16B | CN¥10.1B | CN¥10B | CN¥9.24B | CN¥10.5B | CN¥14.7B | |
| Other investing | CN¥4M | CN¥2.5M | -CN¥148M | -CN¥5.1M | -CN¥17.2M | -CN¥4.08M | CN¥252M | CN¥291M | CN¥834M | CN¥135M | |
| Investing cash flow | -CN¥572M | -CN¥349M | CN¥859M | -CN¥2.57B | -CN¥5.18B | -CN¥2.7B | -CN¥1.44B | -CN¥999M | -CN¥1.17B | -CN¥6.51B | |
| Financing | |||||||||||
| Net debt issued / repaid | CN¥0 | CN¥10M | CN¥282M | CN¥33M | CN¥355M | CN¥1.21B | CN¥715M | CN¥418M | -CN¥704M | -CN¥38.7M | |
| Share buybacks | -CN¥1K | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | |
| Other financing (incl. tax on vested shares) | -CN¥26.6M | -CN¥24.8M | CN¥4.15B | -CN¥98.5M | -CN¥105M | -CN¥155M | CN¥45.9M | -CN¥86.4M | CN¥13.5M | CN¥48.4M | |
| Financing cash flow | CN¥1.64B | CN¥89.4M | CN¥4.43B | CN¥2.11B | CN¥4.91B | CN¥5B | CN¥2.89B | CN¥2.59B | -CN¥607M | CN¥4.73B | |
| Summary | |||||||||||
| FX effect on cash | CN¥22.4M | -CN¥26.9M | CN¥63.8M | CN¥25.3M | -CN¥569M | -CN¥197M | CN¥119M | -CN¥6.88M | CN¥12.7M | -CN¥116M | |
| Net change in cash | CN¥727M | -CN¥779M | CN¥4.34B | -CN¥2.1B | -CN¥1.15B | CN¥83.2M | -CN¥343M | CN¥1.73B | -CN¥472M | CN¥8.1B | |
| Free cash flow (OCF - capex) | -CN¥421M | -CN¥583M | -CN¥1.33B | -CN¥2.03B | -CN¥1.08B | -CN¥3.87B | -CN¥3.3B | -CN¥1.24B | -CN¥418M | CN¥9.32B | |
Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in CNY.
Operating cash flow, capex, free cash flow
quarterlyUses of cash vs operating cash flow
fiscal yearsShare count and EPS
quarterly, dilutedThe other statements
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings.
Data as of 2026-11-02 · Amounts in CNY as reported; price and market cap in HKD.